Ki 16425 has been used as a chemical inhibitor to study the regulation of LPA (lysophosphatidic acid) on LPAR(LPA receptor) subtypes.[1]
Biochem/physiol Actions
Ki16452 is a potent antagonist of the lysophosphatidic acid receptors LPA1 and LPA3, with greater than 30-fold selectivity for LPA1 over LPA2. The Ki values for LPA1 and LPA3 are 250 nM and 360 nM, respectively.
Ki16452 is a potent antagonist of the lysophosphatidic acid receptors LPA1 and LPA3.
Ki 16425 possesses a short-lived inhibitory activity. It has been studied that Ki 16425 is effective in the inhibition of neuropathic pain‐like behaviors.
Discover Bioactive Small Molecules for Lipid Signaling Research
Evidence for lysophosphatidic acid 1 receptor signaling in the early phase of neuropathic pain mechanisms in experiments using Ki?16425, a lysophosphatidic acid 1 receptor antagonist.
Journal of the American Society of Nephrology : JASN, 18(12), 3110-3118 (2007-11-16)
Tubulointerstitial fibrosis in chronic renal disease is strongly associated with progressive loss of renal function. We studied the potential involvement of lysophosphatidic acid (LPA), a growth factor-like phospholipid, and its receptors LPA(1-4) in the development of tubulointerstitial fibrosis (TIF). Renal
Multiple sclerosis (MS) is a neuroinflammatory disease whose pathogenesis remains unclear. Lysophosphatidic acid (LPA) is an endogenous phospholipid involved in multiple immune cell functions and dysregulated in MS. Its receptor LPA1 is expressed in macrophages and regulates their activation, which